Prima BioMed Changes Its Name to Immutep Ltd
2017年11月20日 - 3:59PM
Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (“Prima” or the
“Company”) has announced a rebranding of the Company from Prima
BioMed Ltd to Immutep Ltd (“Immutep”) following shareholder
approval at its Annual General Meeting on 17 November 2017.
Following the acquisition of Immutep S.A.S (the
Company’s 100% owned subsidiary in France) in December 2014 and
subsequent sale under license of the Company’s former cancer
vaccine CVac to Sydys Corporation, its sole focus has been on
developing its portfolio of LAG-3 based immunotherapy assets.
The name Immutep has a strong association with
LAG-3 and its founder, Prima’s Chief Scientific Officer and Chief
Medical Officer, Dr. Frederic Triebel. Additionally, many of the
Company’s clinical partner associations are with Immutep and
several patents remain registered under the Immutep name.
CEO Marc Voigt said: “As the global leader in
LAG-3, the name Immutep better represents our corporate identity
and activities. As it is already embedded in our day to day
operations, costs associated with the rebrand will be minimal so it
makes both strategic and economic sense. Immutep is already
associated with LAG-3 and we see this as an important step in
building awareness of our market position and exciting asset
portfolio.”
Subject to relevant regulatory approvals, the
Company’s new ASX Code will be ‘IMM’ and its new Nasdaq code will
be ‘IMMP’.
The effective date for the name change and the
ticker codes on the ASX and NASDAQ will be on or around the
commencement of trading on Friday, 1 December 2017.
Further shareholder information regarding the
change of name can be accessed on the Company’s website
www.primabiomed.com.au.
About Prima BioMed
Prima is listed on the Australian Securities
Exchange and on the NASDAQ in the US.
For further information please
contact:
U.S. Investors:Jay Campbell,
Vice President of Business Development and Investor Relations,
Prima BioMed+1 (917) 860-9404; jay.campbell@primabiomed.com.au
Matthew Beck, The Trout Group LLC+1 (646)
378-2933; mbeck@troutgroup.com
Australian
Investors/Media:Matthew Gregorowski, Citadel-MAGNUS+61 2
8234 0105; mgregorowski@citadelmagnus.com
Immutep Limited (NASDAQ:PBMD)
過去 株価チャート
から 8 2024 まで 9 2024
Immutep Limited (NASDAQ:PBMD)
過去 株価チャート
から 9 2023 まで 9 2024